Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07287670 · ClinicalTrials.gov registry record · Phase 2
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Phase 2 study, sponsored by Mediar Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
NCT07287670 is a Phase 2 study that is actively recruiting participants, run by Mediar Therapeutics. The registered enrollment target is 85 participants.
The verdict
NCT07287670, a Phase 2 study, is actively recruiting participants, sponsored by Mediar Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
Study Summary
A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Interventions
- OTHER Placebo
- BIOLOGICAL MTX-474
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2026-04-16 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07287670
The ClinicalTrials.gov registry entry for NCT07287670 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mediar Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07287670 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07287670 about?
NCT07287670 is a clinical study titled "EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)". A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
What is the current status of trial NCT07287670?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2026-04-16. Estimated completion is 2028-12.
What interventions are being tested in trial NCT07287670?
The interventions under investigation include: Placebo (OTHER), MTX-474 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07287670?
This trial is sponsored by Mediar Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.